Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Baheal Pharmaceutical Co., Ltd. (formerly Shanghai Modern Traditional Chinese Medicine Co., Ltd.) is an innovative pharmaceutical company specializing in the modernization of traditional Chinese medicine (TCM) and high-end sustained-release formulations. The company's flagship product, Fuzheng Huayu, is a leading botanical drug for liver fibrosis and the first TCM compound to complete Phase II clinical trials in the United States. Its pipeline also includes Qishe Pills for cervical spondylosis, Annian Granules for menopausal syndrome, and Nida, a once-daily osmotic pump metformin formulation for type 2 diabetes. In July 2024, the company was acquired by Qingdao Baheal Pharmaceutical Co., Ltd. (SZ.301015) for 880 million RMB, integrating its advanced manufacturing and R&D capabilities into Baheal's commercialization platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Modern Traditional Chinese Medicine.